ArticleGut2016

Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.